dna friend

Micromet: More Reasons for Optimism

why is MITI having such a tough time making headway with its stock price if its ALL study is so positive. Both you and Joe rave about it but the street keeps sell sell sell, when do we see buy buy buy from wall street.

beta delta

Roche and Genentech: As the Deal Turns

roche is trying to steal dna the same way IN BEV.. stole anheuser busch..
using a strong euro currency against a somewhat weak US dollar.

roche buying dna will stifle the innovation dna worked so hard to cultivate and lead to an exodus of the real talent of dna... scientists... who dont like big pharma..

GenVec, Inc.: The Biggest Little Biotech

genvecerian.. which specific theories are hog wash..

GenVec, Inc.: The Biggest Little Biotech

genvecerian. Let me know when you wish to compare apples to apples.
Genvec's current PACT TRIAL compares
TNFERADE + SOC VS .....SOC only....

The patients exclusions to participate in the SOC and TNFERADE + SOC are the same.. You can quote past statistics for Tarceva, but they are irrelevant for this study. But for my money, Tarceva is not worth the cost with the method of prescribing as of today. Few patients achieve stable disease by the time they are challenged with Tarceva.
Now relating to Genvec's TNFERADE. The current study recently had its endpoint changed per the FDA to OVERALL SURVIVAL, not six months, not one year... OVERALL SURVIVAL. its measured for both the SOC and TNFERADE + SOC. again apples to apples .

All patients in both arms are dealing only with nonresectable patients with stage 1,2,3 tumor burdens. Why not metastatic patients with stage four tumors. Because the survival rates are too low for that patient population and the ability to achieve statistical significance in that patient population would be null. That subset of patients can be tried once approval is gained. Genvec achieves nothing by attempting to cure STAGE 4 patients and attempting to treat them would cause significant financial drain on a company with limited resources.

How can you argue with a look at preliminary data that shows absolute survival at 71% TNF arm vs 28% SOC arm. in comparable patients populations.
Your conclusions lead me to believe you have a financial incentive to see the pact trial fail.

Vanda Pharmaceuticals' Pipeline Nearing FDA Stage

u might want to look at genvec ..(gnvc) and (imgn) both companies have large preclinical /phase 1/2 pipelines and could be breakout candidates very soon

2 Biotech ETFs Differ Greatly in Constituents

etf's are nice.. but they trade like a mutual fund and the holdings are subject to change... i prefer the small to midcap biotechs like gnvc and imgn... though they are both small market capwise.. they pack huge potential .. even if u just trade the ranges....

The "Naked" Truth About Antibodies For Cancer Therapy

hammertime.. could you write an article on immunogen (imgn). IMGN has many partners as you know.
DNA and AVE being the most prevalent. DNA currently owns 3 other licenses to bring new tap conjugates into phase trials. Though DNA has not yet identified the targets, patents on file suggest prostate and ovarian cancers, along with NHL being the potential targets for drugs and possibly have trials begin sometime in calendar 2008.

IMGN also likely expects its partners BIIB, CNTO, Biotest, and SAN_AVE to bring conjugates into clinic with the next 18 months.

IMGN will likely have 4-6 new drugs in the clinic by yaer end 2009.

Has Gene Therapy Finally Come of Age?

hey mebane.. do the breakdown for genvec if u will.. i am very long genvec since 1.60 .. and like the buying opportunity currently given..

Hematology Meeting to Boost Amgen, Biogen Idec and Other Biotechs

anyone here follow imgn or alth.. imgn should report data for MM with drug n901-dm1.